[go: up one dir, main page]

KR880013556A - 도파민수용체 효능제의 용도 - Google Patents

도파민수용체 효능제의 용도 Download PDF

Info

Publication number
KR880013556A
KR880013556A KR1019880005250A KR880005250A KR880013556A KR 880013556 A KR880013556 A KR 880013556A KR 1019880005250 A KR1019880005250 A KR 1019880005250A KR 880005250 A KR880005250 A KR 880005250A KR 880013556 A KR880013556 A KR 880013556A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
dopamine receptor
nicotine addiction
receptor agonist
composition according
Prior art date
Application number
KR1019880005250A
Other languages
English (en)
Inventor
스털링 뮐러 페터
Original Assignee
쟝 크래머, 한스 루돌프 하우스
산도즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 쟝 크래머, 한스 루돌프 하우스, 산도즈 리미티드 filed Critical 쟝 크래머, 한스 루돌프 하우스
Publication of KR880013556A publication Critical patent/KR880013556A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

내용 없음

Description

도파민수용체 효능제의 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. 유효량의 직접 도파민수용체효능제(dopamine receptor agonist)를 니코틴중독치료가 필요한 환자에게 투여함을 특징으로 하여, 환자의 니코틴중독을 치료하는 방법.
  2. 니코틴중독을 치료하기 위한 직접 도파민수용체효능제의 용도.
  3. 니코틴중독치료용 약제학적조성물을 제조하기 위한 직접 도파민수용체효능제의 용도.
  4. 활성제로서 직접 도파민수용체효능제를 혼입시킨, 니코틴중독치료용 약제학적조성물.
  5. 제4항에 있어서, 담배소비량억제용 약제학적조성물.
  6. 제5항에 있어서, 담배를 끊거나 줄이기 위한 약제학적조성물.
  7. 제4항에 있어서, 활성제가 유리염기형태 또는 약제학적으로 허용되는 산부가염형태의 브로모크립틴인 약제학적조성물
  8. 제7항에 있어서, 유리염기형태 또는 약제학적으로 허용되는 산부가염형태의 브로모크립틴을 단위용량당 0.5 내지 2.5mg함유하는 약제학적조성물
    ※ 참고사항 : 최초출원내용에 의하여 공개하는 것임.
KR1019880005250A 1987-05-07 1988-05-06 도파민수용체 효능제의 용도 KR880013556A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4775387A 1987-05-07 1987-05-07
US07/047,753 1987-05-07

Publications (1)

Publication Number Publication Date
KR880013556A true KR880013556A (ko) 1988-12-21

Family

ID=21950776

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880005250A KR880013556A (ko) 1987-05-07 1988-05-06 도파민수용체 효능제의 용도

Country Status (13)

Country Link
JP (1) JPS63287723A (ko)
KR (1) KR880013556A (ko)
AU (1) AU622614B2 (ko)
CH (1) CH675834A5 (ko)
DE (1) DE3814521A1 (ko)
DK (1) DK245388A (ko)
FR (1) FR2614789B1 (ko)
GB (1) GB2204240B (ko)
IT (1) IT1219564B (ko)
NL (1) NL8801171A (ko)
PH (1) PH25495A (ko)
SE (1) SE8801708L (ko)
ZA (1) ZA883237B (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797405A (en) * 1987-10-26 1989-01-10 Eli Lilly And Company Stabilized pergolide compositions
US6623752B1 (en) 1996-07-02 2003-09-23 Hexal Ag Patch for transdermal application for pergolid
DE19626621A1 (de) * 1996-07-02 1998-01-08 Hexal Ag Pflaster zur transdermalen Anwendung von Pergolid

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR861128B (en) * 1985-05-06 1986-08-26 Sandoz Ag New use of dopamine agonists
DE3722383A1 (de) * 1986-07-14 1988-01-28 Sandoz Ag Neue verwendung von bromocriptin

Also Published As

Publication number Publication date
FR2614789B1 (fr) 1991-10-18
DE3814521A1 (de) 1988-11-17
ZA883237B (en) 1990-01-31
GB2204240A (en) 1988-11-09
DK245388A (da) 1988-11-08
GB2204240B (en) 1991-04-24
SE8801708L (sv) 1988-11-08
GB8810509D0 (en) 1988-06-08
AU1560588A (en) 1988-11-10
AU622614B2 (en) 1992-04-16
NL8801171A (nl) 1988-12-01
DK245388D0 (da) 1988-05-05
JPS63287723A (ja) 1988-11-24
PH25495A (en) 1991-07-24
FR2614789A1 (fr) 1988-11-10
IT8847906A0 (it) 1988-05-03
SE8801708D0 (sv) 1988-05-05
IT1219564B (it) 1990-05-18
CH675834A5 (ko) 1990-11-15

Similar Documents

Publication Publication Date Title
ES2164040T1 (es) Uso de agonistas del sitio de union de la glicina o de inhibidores de la absorcion de la glicina para el tratamiento de trastornos neuropsiquiatricos.
KR900701282A (ko) 심장 또는 뇌의 허혈성 질환의 치료, 예방제
KR920702216A (ko) 아세틸 d-카르니틴의 녹내장 치료에의 용도
KR900700089A (ko) 전신성 피부 투과적 투여를 위한 약학적 조성물
KR970009799A (ko) 물질 남용 금단의 치료 방법
RS49918B (sr) Upotreba glp-1, ili analoga za lečenje infarkta miokarda
KR880002515A (ko) 흡수 및 작용이 빠른 설린다크 또는 나트륨 설린다크와 염기의 혼합물
KR920703041A (ko) 통증을 수반하는 염증성 또는 알레르기성 질환치료에 사용되는 성분물과 그 방법
CA2270955A1 (en) Pharmaceutical composition containing morphinan derivative for treating drug dependence
KR970025615A (ko) 암 전이 억제제
WO2002034267A8 (de) Kombination eines transdermalen therapeutischen systems und einer oralen und/oder parenteralen zubereitung enthaltend dopaminagonisten zur behandlung dopaminerger erkrankungen
KR880007073A (ko) 의 약 품
KR900016135A (ko) 피부 및 점막-상피의 질환 치료용 4-퀴놀린 카복실산 유도체
KR830002510A (ko) 생물학적 활성화합물과 하이드록시알킬 전분으로 구성되는 조성물
BR0211855A (pt) Medicamento e método para tratamento e melhoria da qualidade restauradora do sono
KR950701922A (ko) 치환된 트리아졸의 설페이트 염, 이를 포함하는 약제학적 조성물 및 치료요법에서의 이의 용도(The sulphate salt of a substituted triazole, pharmaceutical compositions thereof and their use in therapy)
KR880013556A (ko) 도파민수용체 효능제의 용도
KR970701191A (ko) 복소환 화합물
MX9203361A (es) Composiciones farmaceuticas que contienen cloruro de galio.
KR920702225A (ko) 약학 조성물
US4476115A (en) Analgesic composition and method of treating subdermal pain
KR880004810A (ko) 소화성 궤양 치료제
KR890007728A (ko) 진통제 제조방법
KR900017599A (ko) 종양 치료용 약학 조성물
KR910004190A (ko) 온단세트론의 신규 의학 용도

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19880506

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19930506

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19880506

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19961007

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 19970210

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 19961007

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I